Skip to content

Daily IssueFutureof Work

·

Daily Issue → inbox:

FFeed EExplore BBuild RRoles AAlerts YYou

●Last issue 3d ago

Anodyne Nanotech | Funded Work

← Back to explore

Anodyne Nanotech

theheropatch.com Company LinkedIn →

Biotech

Advance HeroPatch and ANN-101, next-generation transdermal drug delivery.

Anodyne Nanotech is a clinical-stage biotech company, developing transdermal premium products for the treatment of chronic diseases.

Press

Anodyne Nanotech Closed a $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch into Phase I Clinical TrialsBusiness Wire · 6/24/2026
Anodyne Nanotech Appoints Jeff Mihm to its Board of Directorscitybiz · 2/6/2023
Anodyne Nanotech Achieves Breakthrough in Transdermal Delivery of GLP-1 DrugsBusiness Wire · 12/19/2024
Anodyne Nanotech Closed a $12.6 Million Series A to Advance Once-Weekly GLP-1 Patch into Phase I Clinical TrialsThe National Law Review · 6/24/2026

Funding Timeline

6/25/2026series_a$13M

6/25/2026Series A$13M